Advaxis (NASDAQ:ADXS) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Advaxis (NASDAQ:ADXS) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P. “

A number of other analysts have also issued reports on ADXS. HC Wainwright reissued a neutral rating on shares of Aerpio Pharmaceuticals in a research report on Wednesday, June 12th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.

Shares of NASDAQ ADXS opened at $1.55 on Monday. Advaxis has a 52-week low of $1.50 and a 52-week high of $24.60. The firm has a 50 day moving average price of $2.38.

Several large investors have recently bought and sold shares of the business. Deutsche Bank AG raised its holdings in shares of Advaxis by 5,970.3% in the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 553,031 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Advaxis by 2,468.2% in the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 355,415 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Advaxis by 3.1% in the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 43,368 shares in the last quarter. Institutional investors and hedge funds own 24.40% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: What is Liquidity?

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.